Adc Therapeutics Sa Stock Z Score
| ADCT Stock | USD 4.78 0.19 3.82% |
ADC | Z Score |
ADC Therapeutics SA Company Z Score Analysis
ADC Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
ADC Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for ADC Therapeutics is extremely important. It helps to project a fair market value of ADC Stock properly, considering its historical fundamentals such as Z Score. Since ADC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ADC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ADC Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, ADC Therapeutics SA has a Z Score of 0.0. This is 100.0% lower than that of the Communications Equipment sector and 100.0% lower than that of the Information Technology industry. The z score for all United States stocks is 100.0% higher than that of the company.
ADC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ADC Therapeutics from analyzing ADC Therapeutics' financial statements. These drivers represent accounts that assess ADC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADC Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.0B | 2.1B | 1.6B | 300.1M | 135.6M | 128.9M | |
| Enterprise Value | 1.9B | 1.7B | 1.2B | 91.0M | (18.6M) | (17.6M) |
ADC Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in ADC Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ADC Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ADC Therapeutics' value.| Shares | Jane Street Group, Llc | 2023-12-31 | 101.3 K | Indie Asset Partners, Llc | 2023-12-31 | 92.7 K | Miracle Mile Advisors, Inc. | 2023-12-31 | 84.5 K | Hrt Financial Llc | 2023-12-31 | 80.1 K | Hennion & Walsh Asset Management Inc | 2023-12-31 | 65.9 K | Magnetar Financial Llc | 2023-12-31 | 55.8 K | Xtx Topco Ltd | 2023-12-31 | 43.6 K | Marshall Wace Asset Management Ltd | 2023-12-31 | 21.8 K | Susquehanna International Group, Llp | 2023-12-31 | 20.7 K | Prosight Management, Lp | 2023-12-31 | 6.5 M | Goldman Sachs Group Inc | 2023-12-31 | 2.9 M |
ADC Fundamentals
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (2.22) % | ||||
| Current Valuation | 535.59 M | ||||
| Shares Outstanding | 82.53 M | ||||
| Shares Owned By Insiders | 29.00 % | ||||
| Shares Owned By Institutions | 41.17 % | ||||
| Number Of Shares Shorted | 993.08 K | ||||
| Price To Earning | 19.80 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 5.21 X | ||||
| Revenue | 69.56 M | ||||
| Gross Profit | 35.1 M | ||||
| EBITDA | (145.78 M) | ||||
| Net Income | (240.05 M) | ||||
| Cash And Equivalents | 376.78 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 124.38 M | ||||
| Debt To Equity | 2.75 % | ||||
| Current Ratio | 5.76 X | ||||
| Book Value Per Share | (1.80) X | ||||
| Cash Flow From Operations | (118.69 M) | ||||
| Short Ratio | 1.74 X | ||||
| Earnings Per Share | (2.94) X | ||||
| Price To Earnings To Growth | 0.74 X | ||||
| Target Price | 10.2 | ||||
| Number Of Employees | 273 | ||||
| Beta | 1.74 | ||||
| Market Capitalization | 410.17 M | ||||
| Total Asset | 354.78 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 268.62 M | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 288.7 M | ||||
| Net Asset | 354.78 M |
About ADC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ADC Therapeutics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ADC Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ADC Therapeutics' short interest history, or implied volatility extrapolated from ADC Therapeutics options trading.
Pair Trading with ADC Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ADC Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ADC Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with ADC Stock
| 0.65 | AVNW | Aviat Networks Earnings Call This Week | PairCorr |
Moving against ADC Stock
| 0.81 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.67 | DZSI | DZS Inc Financial Report 13th of May 2024 | PairCorr |
| 0.64 | AAPL | Apple Inc Earnings Call This Week | PairCorr |
| 0.53 | MX | MagnaChip Semiconductor Earnings Call This Week | PairCorr |
| 0.51 | INTC | Intel Earnings Call Today | PairCorr |
The ability to find closely correlated positions to ADC Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ADC Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ADC Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ADC Therapeutics SA to buy it.
The correlation of ADC Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ADC Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ADC Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ADC Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ADC Therapeutics Piotroski F Score and ADC Therapeutics Valuation analysis. Note that the ADC Therapeutics information on this page should be used as a complementary analysis to other ADC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for ADC Stock analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is ADC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADC Therapeutics. If investors know ADC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Revenue Per Share 0.851 | Quarterly Revenue Growth (0.76) | Return On Assets (0.25) | Return On Equity (7.06) |
The market value of ADC Therapeutics is measured differently than its book value, which is the value of ADC that is recorded on the company's balance sheet. Investors also form their own opinion of ADC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ADC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADC Therapeutics' market value can be influenced by many factors that don't directly affect ADC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.